CareLit · DOI-Nachweis · Pneumologie
Subgroup analysis: AIRLEAF® Phase II study of a dipeptidyl peptidase 1 (DPP1, or CatC) inhibitor, verducatib, in adults with non–cystic fibrosis bronchiectasis
DOI 10.1055/s-0046-1826150
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ D Chalmers, M Shteinberg, A E O'Donnell, H Watz, L Li, J Rauch, S H Chotirmall, N Hasegawa, W Sauter, A Gupta, M A Mall
ZeitschriftPneumologie
Ausgabe10/2026
Jahrgang / SeitenJg. 80 · S. e68-e69
Kernaussage aus der Literatur
Abstract-Vorschau
Subgroup analysis: AIRLEAF® Phase II study of a dipeptidyl peptidase 1 (DPP1, or CatC) inhibitor, verducatib, in adults with non–cystic fibrosis bronchiectasis
Zitieren
Zitierempfehlung
J D Chalmers, M Shteinberg, A E O'Donnell, H Watz, L Li, J Rauch, S H Chotirmall, N Hasegawa, W Sauter, A Gupta, M A Mall (2026) Subgroup analysis: AIRLEAF® Phase II study of a dipeptidyl peptidase 1 (DPP1, or CatC) inhibitor, verducatib, in adults with non–cystic fibrosis bronchiectasis. Pneumologie, 80 (10), e68-e69. https://doi.org/10.1055/s-0046-1826150
Mit CareLit weiterarbeiten